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  Despite the intensive vaccination policy that has been put in 
place to control Newcastle disease virus (NDV), the recent 
emergence of NDV genotype VII strains in Korea has led to 
significant  economic  losses  i n  t h e  p o u l t r y  i n d u s t r y .  W e  
assessed  the  ability  of  inactivated,  oil-emulsion  vaccines 
derived from La Sota or Ulster 2C NDV strains to protect 
chickens from challenge with Kr-005/00, which is a recently 
isolated Korean epizootic genotype VII strain. Six-week-old 
SPF chickens were vaccinated once and challenged three 
weeks later via the eye drop/intranasal route. All vaccinated 
birds were fully protected from disease, regardless of the 
vaccine strains used. All vaccinated and challenged groups 
showed significant sero-conversion 14 days after challenge. 
However, some vaccinated birds, despite being protected 
from disease, shed the challenge virus from their oro-pharynx 
and  cloaca,  albeit  at  significan t l y  l o w e r  t i t e r s  t h a n  t h e  
unvaccinated  challenged  control  birds.  The  virological, 
serological,  and  epidemiological  significance  of  our 
observations  with  regard  to  NDV  disease  eradication  is 
discussed.
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Introduction 
  Newcastle disease (ND) is caused by the ND virus (NDV) 
and it is one of the most important diseases that affects 
birds, in particular chickens. The epizootic nature of the 
disease has caused severe economic losses in the poultry 
industry worldwide since the 1920s. NDV is a member of 
the avian paramyxovirus type 1 viruses that belong to the 
Avulavirus genus of the Paramyxoviridae family [17]. 
      NDV strains can be classified into three pathotypes 
(lentogenic, mesogenic and velogenic) on the basis of the 
severity of disease they cause in chickens. Severity is 
determined by in vivo pathogenicity test parameters, 
including the mean death time in specific pathogen-free 
(SPF) chicken embryos and the intra-cerebral pathogenicity 
index in day-old SPF chickens [1]. A lethal infection by a 
velogenic NDV pathotype results in high mortality (up to 
100%) in chickens and a severe drop in the egg 
productivity of laying hens. Molecular biologically, 
multiple basic amino acids at the C-terminus of the F2 
protein and phenylalanine at residue 117, which is the 
N-terminus of the F1 protein, have been demonstrated in 
the virulent virus [18].
    Within the single NDV serotype, eight genotypes 
(designated I to VIII) have been determined by restriction 
site mapping and sequence analysis of the fusion (F) gene 
[2,6,21]. Since the 1920s, at least four genotypes (III, V, VI 
and VII) have been responsible for epizootic episodes in 
Korea [10,11]. A genotype III virus was involved in the 
first epizootic episode, which took place before the 1960s 
[11]. Genotypes V and VI viruses were most common 
during the second epizootic (before 1984) and third 
epizootic episodes (the late-1980s to mid-1990s) [10,11]. 
A genotype VII virus first emerged in 1984 and then 
reemerged in 1995. This genotype was prevalent during the 
most recent “epizootic episode”, which has been ongoing 
since the 2000s [11]. 
  To contain the spread of NDV, chickens are routinely 
vaccinated with NDV vaccines derived from known strains 
such as La Sota or Ulster 2C. Many researchers have 
recently reported that the viruses isolated in Korea, China, 
Japan and Taiwan belong to the VIId sub-genotype of 
genotype VII [4,8,11,13,14,16,20-22]. Some of these 
isolates, including the Korean isolate Kr-005/00, were 
obtained from chickens that had been vaccinated several 
times with current NDV vaccines [4,22]. This suggests that 
these VIId isolates are antigenically distinct from the 296    Woo-Jin Jeon et al.
currently available NDV vaccine strains. Alternatively, it 
is possible that the vaccines are not sufficiently 
immunogenic to prevent the spread of NDV. 
  In this paper, we assessed the ability of two commercial 
oil-emulsion NDV vaccines based on the La Sota or Ulster 
2C strains to protect chickens from the recently isolated 
Korean epizootic sub-genotype VIId isolate, Kr-005/00. 
For comparison, we also challenged the vaccinated 
chickens with Kr-KJW/49, which is the standard genotype 
III challenge strain used in Korea [11]. 
Materials and Methods
Chickens 
  Six-week-old, SPF chickens from White Leghorn parents 
(Lohmann, Germany) were used in this study. Before the 
chickens were introduced into the laboratory experimental 
facilities of the National Veterinary Research and 
Quarantine Service of Korea, they were tested for the 
major viral diseases that affect chickens, including NDV, 
infectious bursal disease, and infectious bronchitis. The 
SPF birds were maintained in air-filtered bio-security 
isolation units (ThreeShine, Korea) with feed and water ad 
libitum for the duration of the study. All experiments were 
performed at animal facilities which followed the ethical 
guidelines of animal welfare committee recommended by 
the National Veterinary Research and Quarantine Service. 
Viruses 
    The two highly virulent NDV strains Kr-005/00 and 
Kr-KJW/49 were used for challenge in this study. The 
sub-genotype VIId Kr-005/00 strain was isolated from a 
laying chicken that had been routinely vaccinated with live 
and inactivated vaccines during the recent epizootic episode 
in Korea in 2000 [11]. The genotype III Kr-KJW/49 strain 
was originally isolated in 1949 from a dead chicken that 
had been raised free in a backyard in Korea. All viruses 
were propagated using SPF chicken eggs, titrated as 
described elsewhere [9], and stored at -70
oC until use. 
Animal experiments 
  Seventy-three SPF chickens were divided into nine groups 
(Table 1). Two locally-produced, inactivated, oil-emulsion 
vaccines that were derived from La Sota or Ulster 2C were 
used in this study. Fifty-eight birds were immunized via the 
intramuscular route with a single dose of the La Sota 
vaccine (n = 29) or the Ulster 2C vaccine (n = 29), according 
to the manufacturer’s recommendations. Fifteen birds 
were not vaccinated and served as a control group. Three 
weeks post-vaccination (pv), birds in each vaccine group 
were challenged with Kr-005/00 (10
4.5 EID50/100 μl) (n = 
12 per vaccine group) or Kr-KJW/49 (10
4.8 EID50/100 μl ) 
(n = 12 per vaccine group) via the eye drop (50 μl) and 
intranasal (50 μl) routes (ED/IN route). Unvaccinated birds 
were also challenged with Kr-005/00 (n = 5) or Kr-KJW/49 
(n = 5) as described above. Fifteen birds, including five 
unvaccinated, five La Sota-vaccinated, and five Ulster 
2C-vaccinated birds, were sham challenged with the same 
volume (100 μl) of PBS via the ED/IN route. All birds were 
monitored daily for overt clinical signs (depression, respiratory 
signs, diarrhea etc) and mortality. Serum samples were 
taken by wing bleeds on day 0 pv, 0 post-challenge (pc) and 
14 pc. Oro-pharyngeal and cloacal swabs were collected 
from birds on day 0, 1, 3, 5, 7, 10 and 14 pc. 
Virus isolation 
  Swab samples collected for virus isolation were placed in 
3 ml transport medium (Micro Test M4RT; Remel, USA) 
and stored at -70
oC until use. For viral isolation, the 
samples were clarified by centrifugation at 3,000 × g for 10 
min. A 100-μl aliquot of the supernatant was serially 
diluted 10-fold and inoculated onto monolayers of primary 
chicken embryo fibroblast cells in 96-well tissue culture 
microtitre culture plates (Nunc, Denmark). The cells were 
incubated for five d at 37
oC and observed daily for 
cytopathic effects, which are characterized by scattered 
focal areas of cell rounding and syncytia formation. 
Serology 
  Serum titers to NDV were determined by hemagglutination 
inhibition (HI) tests in U-bottom microtiter plates as 
described elsewhere [1]. Two-fold dilutions of test sera in 
PBS (pH 7.4) were mixed with the same volume of La Sota 
antigen (4 HA units). The mixture (50 μl per well) was then 
incubated at room temperature for 30 min. Fifty μl of 0.5% 
chicken RBC in PBS was then added. The HI endpoint was 
determined as the last dilution that showed complete 
inhibition of HA activity. All tests were repeated twice. HI 
titers are expressed as reciprocal log2 in this study. 
Statistical analysis 
  A three-way ANOVA and paired t-test were performed to 
evaluate the influence of multiple variables on the 
serological data. The vaccine strain (La Sota or Ulster 2C), 
the challenge virus (Kr-005/00 or Kr-KJW/49), and the test 
time (0 day pc or 14 day pc) served as independent 
variables. Variation among these three variables was 
analyzed by using a three-way ANOVA. Variation in the 
antibody titers at 0 day pc and 14 day pc within each factor 
category was analyzed by using paired t-test. Variation 
between or within groups was considered to be significant 
at p ＜ 0.05.
Results
Protection  of  vaccinated  SPF  chickens  against 
challenge 
  No overt clinical signs of ND were observed in any birds Protective efficacy of NDV vaccines    297
Table 1. Protection of vaccinated SPF chickens with inactivated oil-emulsion vaccines against challenge with virulent Newcastle 
disease virus 
Challenge* Protection
†
Group HI titer (log2) 
(Vaccine Strain) prior to challenge
Strain Route No. birds Clinical signs Mortality
La Sota 5.2 ± 1.4 Kr-005/00 ED/IN 12 0/12      0% (0/12)
4.3 ± 1.9 Kr-KJW/49 ED/IN 12 0/12     0% (0/12)
5.4 ± 1.3 PBS ED/IN 5 0/5     0% (0/5)
Ulster 2C 7.5 ± 1.1 Kr-005/00 ED/IN 12 0/12     0% (0/12)
6.6 ± 1.3 Kr-KJW/49 ED/IN 12 0/12     0% (0/12)
5.8 ± 2.6  PBS ED/IN 5 0/5     0% (0/5)
Control 0 Kr-005/00 ED/IN 5 5/5 100% (5/5)
0 Kr-KJW/49 ED/IN 5 5/5 100% (5/5)
0 PBS ED/IN 5 0/5    0 % (0/5)
*Six-week-old SPF birds were vaccinated with a commercial inactivated oil-emulsion vaccine and challenged three weeks later with 10
5.0
EID50 of virulent virus via the eye drop and intranasal (ED/IN) route. 
†Protection of chickens against challenge was observed over the two 
weeks following the challenge. 
Table 2. Serologic responses before and after challenge in vaccinated SPF chickens with an inactivated oil-emulsion vaccine
Challenge strain 
Group
Kr-005/00 (VIId) Kr-KJW/49 (III) Sham-challenge
(Vaccine Strain)
0 dpc 14 dpc 0 dpc 14 dpc 0 dpc 14 dpc
Vaccine
    La Sota 5.2 ± 1.4* (n = 12)
a,p   9.3 ± 1.5
b,q 4.3 ± 1.9 (n = 12)
a,p 8.0 ± 2.4
b,q 5.4 ± 1.3 (n = 5)
a,p 5.6 ± 1.8
a,p
    Ulster 2C 7.5 ± 1.1 (n = 12)
a,q 10.0 ± 1.0
b,q 6.6 ± 1.3 (n = 12)
a,q 8.7 ± 1.8
b,q 5.8 ± 2.6 (n = 5)
a,p   6.0 ± 2.4
a,p
    Control       0 (n = 5)
c,r NT     0 (n = 5)
c,r NT     0 (n = 5)
c,r 0
*The data are geometric mean HI antibody titers (log2) ± SD. 
a, b, cValues with different superscripts within row differ significantly (p ＜ 0.05).
p, q, rValues with different superscripts within column differ significantly (p ＜ 0.05). dpc: day post challanege.
prior to challenge. Protection from virulent NDV 
challenge was determined by the absence of clinical signs 
and death during the 14 day pc period (Table 1). None of 
the birds that had been vaccinated with a La Sota- or Ulster 
2C-derived vaccine showed clinical signs after challenge 
with Kr-005/00 or Kr-KJW/49. In contrast, 100% of the 
unvaccinated birds that had been challenged with 
Kr-005/00 or Kr-KJW/49 died within 5 day pc. All dead 
birds displayed severe depression between day 2-4 pc. All 
unchallenged birds in each of the three groups remained 
normal during the course of the experiment. 
Serological response of SPF chickens to NDV
  Sera were taken from chickens on day 0 pv, 0 pc, and 14 
pc and the anti-NDV antibody titers were determined by 
the HI test. None of the sham control birds had detectable 
HI antibodies to NDV during the course of the study. The 
serologic results were analyzed by using a three-way 
ANOVA based on three independent variables (Table 2). 
Prior to challenge (0 day pc), the Ulster 2C vaccine group 
had a significantly higher geometric mean HI antibody titer 
compared to that of the La Sota vaccine group (p ＜ 0.05). 
On day 14 after being challenged with Kr-005/00 or 
Kr-KJW/49, both the La Sota- and Ulster 2C-vaccinated 
groups showed significant increases in HI antibody titers 
(paired t-test, p ＜ 0.05). These rises in HI titers between 0 
and 14 day pc were not observed in either non-challenged 
control vaccine group (paired t-test, La Sota group p = 
0.62, Ulster 2C group p = 0.74). The geometric mean HI 
titers on day 0 and 14 pc differed significantly between 
challenge and non-challenge control groups but not 
between the challenge groups.298    Woo-Jin Jeon et al.
Fig. 1. Titers of Newcastle disease virus recovered from oro-pharyngeal and cloacal swabs after SPF chickens that had been vaccinated
with La Sota- or Ulster 2C-derived vaccines were challenged with Kr-005/00 (A) or Kr-KJW/49 (B). OP; oropharyngeal swab, CL; 
cloacal swab.
Table 3. Virus shedding from oro-pharyngeal and cloacal swabs of vaccinated chickens with an inactivated oil-emulsion vaccine after
challenge
Challenge strain
Kr-005/00 Kr-KJW/49 Sham-challenge
Oropharynx Cloaca Oropharynx Cloaca Oropharynx Cloaca
Vaccine
   La Sota (n = 29) 10/12* (83%)
a,p 3/12 (25%)
b,q 9/12 (75%)
a,p 4/12 (33%)
b,q 0/5 (0%)
c,r 0/5 (0%)
c,r
   Ulster 2C (n = 29)   5/12 (42%)
b,q 3/12 (25%)
a,q 5/12 (42%)
b,q 4/12 (33%)
b,q 0/5 (0%)
c,r 0/5 (0%)
c,r
   Control (n = 15)     5/5 (100%)
a,p   5/5 (100%)
a,r   5/5 (100%)
a,p   5/5 (100%)
a,p 0/5 (0%)
c,r 0/5 (0%)
c,r
*The data are the number of birds that shed virus during the experiment / number of test birds. 
a, b, cValues with different superscripts with row
differ significantly (p ＜ 0.05). 
p, q, rValues with different superscripts with column differ significantly (p ＜ 0.05). dpc: day post challanege.
Virus shedding in vaccinated chickens after fatal 
challenge
  Oro-pharyngeal and cloacal swabs were collected from 
the birds on day 0, 1, 3, 5, 7, 10, and 14 pc and subjected to 
virus isolation tests. The results of these tests are presented 
in Table 3 and Fig. 1. NDV was not isolated from any of the 
swabs taken from unchallenged birds. All unvaccinated, 
challenged birds were positive for viral shedding and their 
viral titers increased precipitously after challenge until the 
birds died. The maximal virus titers shed by the 
unvaccinated, Kr-005/00-challenged birds were approximately 
10
5 TCID50/ml on day 5 pc. The unvaccinated, Kr-KJW/ 
49-challenged birds had maximal viral titers of ≥10
7 
TCID50/ml, i.e., at least hundred-fold higher compared to 
the unvaccinated, Kr-005/00-challenged birds.
   In  the  vaccinated,  Kr-005/00-challenged birds, NDV 
was isolated from 83% and 42% of the oropharyngeal 
swabs from the La Sota- and Ulster 2C-vaccinated birds, 
respectively, and from 25% of the cloacal swabs collected 
from both the La Sota- and Ulster 2C-vaccinated birds. In 
the vaccinated, Kr-KJW/49-challenged birds, NDV was 
isolated from 75% and 42% of the oropharyngeal swabs 
from the La Sota- and Ulster 2C-vaccinated birds, 
respectively, and from 33% of the cloacal swabs collected 
from both the La Sota- and Ulster 2C-vaccinated birds. 
  The patterns of virus shedding by each challenge group 
are presented in Fig. 1. The titer of viral load is represented 
as the highest titers measured in each group at sampling 
time. These data show that unvaccinated animals revealed 
skyrocketed rise prior to death in viral shedding from both 
swab sites. All vaccinated animals challenged with 
Kr-005/00 showed peak titer in the oro-pharynx and cloaca 
(10
3.0 TCID50/ml) on day 3 and 5 pc, respectively. In 
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showed prolonged duration of virus shedding. Briefly, the 
La Sota-vaccinated animals showed peak titer in the 
oro-pharynx (10
3.0 TCID50/ml) until day 5 pc and in the 
cloaca (≥10
2.0 TCID50/ml) up to day 10 pc. The Ulster 
2C-vaccinated animals showed peak titer in the 
oro-pharynx and cloaca (10
2.0 TCID50/ml) on day 3 and 7 
pc, respectively. It indicates that virus shedding started 
from the oropharynx before cloacal shedding commenced. 
  Viral shedding titers from the La Sota-vaccinated birds 
(average log2 HI titers of 4.3 to 5.2) after challenge were 
lower than the Ulster-vaccinated birds (average log2 HI 
titers of 6.6 to 7.5) regardless of the challenge strain that 
was used. This seems to be related with the titers of HI 
antibodies that were induced by vaccination (Table 1). 
While all vaccinated birds (8 birds) that had an log2 HI titer 
of ≤ 4 at challenge exhibited virus shedding from their 
oropharynx or cloaca, NDV was not recovered from birds 
(11 birds) that had log2 HI titers exceeding 8 at challenge. 
This was true regardless of the vaccine strain that was used. 
Discussion
  Analysis of the NDV strains that were recently isolated 
from vaccinated flocks in China, Taiwan and Korea has led 
several researchers to suggest that the antigenic variant 
genotype VII may be responsible for the continuing 
outbreaks of ND in Asia. Here, we assessed whether a 
genotype VII isolate can overcome the immunity of 
chickens induced by the currently available ND vaccines. 
We found that these vaccines provide chickens with full 
protection from disease caused by the genotype VII virus, 
as no mortality or disease symptoms were observed in any 
of the vaccinated chickens. The vaccines were also 
protective against Kr-KJW/49, which is a previously 
prevalent NDV strain (genotype III). Our results support 
the data reported by Lui et al. [14] that demonstrated that 
chickens vaccinated with the La Sota strain were fully 
protected from challenge with heterologous NDV strains 
of different genotypes. 
  Although none of the chickens vaccinated once with a La 
Sota- or Ulster 2C-derived vaccine became sick or died 
upon challenge in our study, most shed the challenge virus 
from their oropharynx and cloaca (although at 
considerably lower levels than those shed by unvaccinated 
chickens). Similar findings were also reported by 
Kapcynsky and King [7]. We also found that some of 
infected birds commenced viral shedding from their cloaca 
after virus shedding from their oropharynxes. This indicates 
systemic dissemination in the some of infected birds 
(especially with low log2 HI titers ≤ 4), despite vaccination. 
These observations suggest that vaccinated chickens may 
still act as reservoirs and be a source of NDV spread within 
and between farms, especially via their faeces or 
faeces-contaminated materials (i.e., eggs, vehicles and 
people). 
  In this study, the pattern of viral load in chickens infected 
with Kr-KJW/49 was significantly different from that in 
chickens infected with the Kr-Kr005/00. In the 
unvaccinated controls, Kr-KJW/49-challenged birds had 
viral loads 100 times higher than the Kr-005/00-challenged 
birds, despite similar titers of challenge virus. Vaccinated 
birds challenged with Kr-KJW/49 had a prolonged 
duration of virus shedding compared to vaccinated birds 
challenged with Kr-005/00, suggesting re-infection in 
chickens with low HI titers. Thus, birds with lower 
vaccine-induced immunity may continue to be susceptible 
to NDV infection. This may also explain why virulent 
NDV has been isolated from birds despite numerous 
vaccinations and how NDV field viruses can be circulated 
within farms in which chickens were vaccinated routinely 
[4,22]. It should be noted that young broiler chickens, 
having a short life span, are usually vaccinated with live 
attenuated vaccine via various routes (e.g. drinking water, 
sprays, and eye drops). Kapcynski and King [7] found 
significantly lower titers of virus shedding in chickens 
receiving live vaccines compared to chickens receiving 
inactivated NDV vaccines, presumably because of the 
development of stronger mucosal immunity. However, it 
should be noted that live vaccines are predominantly used 
for young birds of several weeks old or less in most of 
countries. Maternal antibodies against NDV can interfere 
with the immune response induced by live vaccine, 
resulting in lower and uneven immunization, depending on 
the level of maternal antibodies against NDV. This 
suggests that some young chickens may susceptible to 
NDV infection and act as reservoirs of NDV spreading. 
    In conclusion, it appears that poor vaccinal immune 
response is responsible for viral spreading rather than viral 
antigenic variation. We found that to protect chickens from 
NDV and prevent them from acting as viral reservoirs, it is 
important to maintain solid and potent immunogenicity by 
efficient vaccination program. In the field, routine 
vaccinations are not inducing sufficiently high levels of 
immunity to control the disease. This is due, presumably, 
to other factors such as maternal antibody interference in 
young chickens, immunosuppression by other agents, poor 
handling or administration of vaccines or inappropriate 
vaccination schedules. Thus, routine vaccinations should 
be supported by high bio-security measures. In this regard, 
the all-in/all-out program can be recommended as one of 
the most effective measures to control the disease. The 
DIVA (differentiation between vaccinated and infected 
animals) strategy that uses marker vaccines, including 
subunit, recombinant, and DNA vaccines [3,5,12,15,18,19], 
may be a tool ideal for removing the source of NDV in 
endemic areas, but it is still not applied to NDV eradication 
in endemic countries such as Korea. Alternatively, it is 
considerable to highlight more strengthened eradication 300    Woo-Jin Jeon et al.
program and financial support and to offer incentives to 
encourage the farmers to report the disease earlier. 
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